



JEAN-FRANCOIS GESTIN

From France to Sweden



Project: **Astatine-211, radiolabeling and automations techniques**

Research topic: **Physics**

Swedish Institution: **Göteborg Universitet**

French Institution: **INSERM**

Dates of mobility: **01/07/2019 to 06/07/2019**

Program: **SFVE-A (ex TOR)**

PRESENTATION

[Jean-François Gestin](#) is Director of Research at [INSERM](#) and the Head Division of Chemistry and Radiochemistry research group. He works at the [Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers \(UMR S 1307\)](#). He is also co-founder of [NaoGen Pharma](#) and the founder of [ISOTOP4LIFE](#) (a French consortium of Industrials and Academic dedicated to market and promote the use of Nuclear for Health) and [CHELATEC](#).

His research focus on Astatine-211, one of the most promising radioelements for targeted alpha radioimmunotherapy, an innovative technology used for cancer treatments.

ACTIVITIES IN SWEDEN

Jean-François Gestin visited [Sture Lindegren](#)'s team, at the [Department of Radiation Physics](#) at [Göteborg Universitet](#), who has developed a strong knowledge in radiolabeling and automation techniques. Jean-François Gestin was interested in their automation knowledge, as his own research group have developed several patented radiolabeling technologies with Astatine-211 that could be improved with this technique. Thus, they exchanged experience on radiolabeling technology, and on how to adapt their labelling procedures to automation for high activity GMP production processes to prepare clinical batches.

Jean-François Gestin also visited [Dr. Holger Jenses](#), Chief Cyclotron Physicists at [Copenhagen University Hospital](#).

Both visits represented the first step for the creation of an EU network dedicated to Astatine chemistry users, as working at a European level would help them to implement concerted actions and exchange good practices and latest developments.